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Abstract
Receptor tyrosine kinase inhibitors have been a standard first-line therapy for renal cell carcinoma (RCC) for over a 
decade. Although they stabilize the disease, they are unable to remove all tumor cells, leading to relapse. Moreover, 
both intrinsic and acquired resistance to therapy are a significant health burden. In order to overcome resistance, 
several combination therapies have been recently approved by the FDA. Another approach takes advantage of altered 
metabolism in tumor cells, which switch to alternative metabolic pathways to sustain their rapid growth and proliferation. 
CB-839 is a small molecule inhibitor of kidney type glutaminase (GLS). GLS is often upregulated in glutamine addicted 
cancers, enhancing glutamine metabolism for the production of energy and the biosynthesis of various cellular building 
blocks. CB-839 is currently in clinical trials for several tumors, including clear cell (cc)RCC, both as monotherapy and in 
combination with the approved therapeutic agents everolimus, cabozantinib and nivolumab. Early results of Phase 1/2 
clinical trials look promising, especially for CB-839 plus cabozantinib, and all combinations seem to be well tolerated. 
However, cancer cells can activate compensatory pathways to overcome glutaminolysis inhibition. Therefore, genetic 
and metabolomic studies are crucial for the successful implementation of CB-839 alone or in combination in subgroups 
of ccRCC patients.
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INTRODUCTION
Renal cell carcinoma (RCC) represents 90% of kidney cancers and 2%-3% of all malignancies. It remains 
the deadliest genitourinary malignancy, with a new case count globally of approximately 270,000 and 
over 100,000 deaths annually[1-3]. Surgery can be performed for early stage localized tumors, however 30% 
of patients present with metastases at the time of diagnosis[4]. Of those who present with non-metastatic 
RCC, many will develop tumors at distant sites, such as brain, lungs, lymph nodes, liver and bone. At this 
stage, the 5-year survival rate is 0%-20%[5]. Drug resistance to currently available therapies is a significant 
issue in the treatment of RCC and can be attributed to very high intra-tumoral heterogeneity (ITH)[6]. It is 
estimated that 25%-30% of patients presenting with advanced RCC do not respond to antiangiogenic drug 
therapy from the beginning, which results in a poor prognosis. Of those who initially respond, most develop 
resistance within 6-15 months after the start of treatment[7-9]. Current efforts aiming at overcoming these 
issues involve combination therapies with already approved targeted therapies and checkpoint inhibitors, as 
well as therapies targeting altered tumor metabolism.
CURRENT STATE OF AVAILABLE THERAPIES
Monotherapies
From the early 1990s until 2006, RCC was treated with interferon-α or interleukin-2 (IL-2). These treatments 
had low rates of efficacy (5%-20%), high morbidity and mortality and are rarely used today. A multi-target 
receptor tyrosine kinase (RTK) inhibitor, sunitinib, was approved by the FDA in 2006 and started the era 
of targeted therapy for RCC[10,11]. Until 2009, when the FDA approved everolimus as a second-line therapy, 
no drugs were available for patients whose disease progressed after initial treatment[12,13]. Other approved 
RTK inhibitors include bevacizumab, axitinib and lenvatinib, all inhibiting vascular endothelial growth 
factor receptors (VEGFR). Pazopanib is another approved small molecule, which works as a multityrosine 
kinase inhibitor. Additionally, cabozantinib inhibits AXL, RET, MET, KIT, FLT3, ROS1, TYRO3 and 
TRKB, as well as VEGFR[12]. Mammalian target of rapamycin (mTOR) is a serine/threonine-specific protein 
kinase frequently mutated in RCC. Examples of mTOR inhibitors include everolimus and temsirolimus[14]. 
Ipilimumab is designed to target Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4), a protein receptor 
which downregulates the immune system by inhibiting T cell proliferation and IL-2 production. Inhibition 
of CTLA-4 leads to reprogramming of T cell metabolism, thus activating these cells. Several programmed 
death-1 (PD-1) receptor inhibitors, such as nivolumab, pembrolizumab and ateozumab, work to increase T 
cell metabolism[12,15]. Despite significant progress in the field, drug resistance remains a significant health 
burden[12].
Combination therapies
Combination therapy is a treatment approach where two or more therapeutics are used together to treat a 
disease. It was first applied to treat cancer in 1965, when Emil Frei, James F. Holland and Emil J. Freirich 
noticed that the treatment of acute leukemia in children using methotrexate, 6-mercaptopurine plus 
vincristine had an additive effect on disease remission[16]. Since then, combination therapies with drugs that 
target different biochemical pathways have been of great focus in cancer research. The objective of these 
studies is to find combinations which have synergistic or additive effects. More recently, efforts have been 
made to develop restrictive combinations, which spare healthy cells but specifically target tumor cells. This 
approach takes advantage of differences between healthy and malignant cells, such as the absence of a drug 
target. This is exemplified by the absence of functional p53 in some tumor cells, where growth of normal 
cells is arrested by one drug in order to protect them from the effect of another drug, which only targets 
actively dividing cells[17]. Drug repurposing is another approach where drugs already approved for use in 
treatment of different diseases could be employed in the cancer setting[18].
Development of combination therapies is on the increase and could one day become a new standard of care. Its 
superiority over monotherapy presents in a potential decrease in drug resistance with concurrent therapeutic 
benefit, such as reduced tumor growth and prevention of metastases. The first FDA-approved combination 
for advanced RCC was lenvatinib plus everolimus as second-line therapy. The approval was based on a better 
outcome over therapy with a single agent and acceptable toxicity[19]. Similarly, following Phase II clinical trials, 
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bevacizumab plus INFα is one of the available first-line treatments in patients presenting with metastatic 
disease[20,21]. Published in April 2018, the Phase III CheckMate 214 study of nivolumab plus ipilimumab vs. 
sunitinib led to the FDA approval of the combination therapy for treatment-naive intermediate- and poor-risk 
patients with advanced RCC. In this study, the combination produced a more favorable overall survival (OS) 
and a higher objective response rate (ORR) in the above-mentioned patient groups, but not in the low-risk 
group. Likewise, it improved progression-free survival (PFS) in comparison to sunitinib, however these results 
did not meet the prespecified statistical significance (P = 0.009)[22,23]. 
One of the treatments awaiting approval by The National Institute for Health and Care Excellence (NICE) 
is atezolizumab plus bevacizumab, which was shown to improve PFS as a first-line treatment of advanced 
or metastatic RCC in comparison to sunitinib[24]. A Phase Ib/II study of lenvatinib plus pembrolizumab 
involved 30 patients with metastatic RCC, of which 21 (70%) developed grade 3 or 4 adverse events (AEs) and 
four discontinued treatment due to the AEs[24]. This study reported manageable AEs and did not identify 
any new safety concerns. A Phase III study of this combination vs. sunitinib is underway[25]. Combinations 
of cabozantinib (Cabo) plus nivolumab (Nivo) and CaboNivo plus ipilimumab were tested in a Phase I study 
and its expansion trial. Both combinations were evaluated for favorable efficacy and tolerability in patients 
with mRCC and other genitourinary malignancies[26,27]. Safety and toxicity of tivozanib plus nivolumab were 
ruled to be acceptable in a Phase Ib study[28]. Of 18 patients, all developed at least one AE and five (38%) 
showed signs of grade 3-4 AE. Additional patients are currently being enrolled and treated in a Phase II trial 
that aims to evaluate combination efficacy[28]. 
NOVEL APPROACHES FOR THE TREATMENT OF RCC
Glutamine addiction
Over the past few years, cancer cell metabolism has gained significant interest in the research community 
and metabolic reprogramming is now recognized as one of the hallmarks of cancer[29]. In order to sustain 
their rapid growth, malignant cells switch to alternative metabolic pathways, which allow them to increase 
energy and nutrient production. Cancer cells are largely dependent on aerobic glycolysis, also known as 
“the Warburg effect”, whereas normal cells generate energy by oxidative phosphorylation in mitochondria. 
Malignant cells may also rely on a non-essential amino acid, glutamine, which can be as equally important 
as glucose for the survival of tumor cells[30]. In the kidney, glutamine is converted into glutamate by the 
mitochondrial enzyme glutaminase (GLS1). Glutamate can then enter Krebs cycle and act as an intermediate 
for biosynthesis of various molecules, such as nucleotides, amino acids and glutathione[31]. Due to its 
involvement in the pathways mentioned above, glutamine plays an important role in cell proliferation and 
protection against oxidative stress[30]. Moreover, depleted glutamine levels are often found in the tumor 
environment caused by its uptake into cancer cells. This in turn affects T-cell growth, proliferation and 
cytokine production, all of which require high energy input. Glutamine metabolism is thought to be of 
particular importance in T-cell activation[31].
The first small molecule GLS inhibitors, such as 6-diazo-5-oxo-l-norleucine (DON), were first described 
in the 1950s and suggested to be useful in chemotherapy. Such early compounds also included azaserine 
and acivicin[32,33]. All three drugs are glutamine analogues and bind irreversibly to the active site of the 
enzyme, thus inhibiting glutamine binding. Despite promising in vitro data, clinical studies with these 
compounds have been restricted due to limited therapeutic activity and severe toxicities[33,34]. Dose-limiting 
adverse events are likely due to low selectivity and inhibition of other glutamine-utilizing enzymes, such as 
amidotransferases and glutamine synthetase. However, DON has recently been used in clinical studies in 
patients with advanced refractory solid tumors, where its combination with PEGylated glutaminase showed 
therapeutic activity and a tolerable toxicity profile[35]. 
Bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3 (BPTES) is an example of the class of  allosteric 
inhibitors of GLS1. It binds to both free enzyme and enzyme-substrate complexes and forms a stable but 
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inactive tetramer complex[36]. In addition to its high specificity, it is also more effective in inhibiting GLS1 
that DON, with a Ki of 3 µmol/L[37]. Therefore, it is less likely to interact with transporters, receptors or 
other molecules that recognize glutamine or glutamate as their substrates. While it was shown to slow cancer cell 
proliferation in vitro and in xenografts[38], its moderate potency (IC50 = 3.3 μmol/L), poor metabolic stability and 
low solubility, limit its potential use in the clinical setting[39]. 
CB-839 in vitro
CB-839 is a small, orally administered molecule, which inhibits human glutaminase in an allosteric and 
reversible manner [Figure 1]. It exerts a dual action by inhibiting tumor cells and activating T cells[40]. It 
was shown to downregulate mTOR signaling in RCC cell lines and RMPI8226 myeloma cells, as shown 
by a decrease in proteins such as phospho-mTOR and phospho-S6. The same study found a reduction in 
oncogenic proteins c-Myc and c-Kit and an increase in programmed cell death proteins, such as cleaved-
PARP[41]. It also inhibits glutaminase in triple negative breast cancer (TNBC) cell lines, which are highly 
sensitive to glutaminolysis inhibition[42,43]. CB-839 exhibits high specificity towards GLS1, demonstrated 
by suppression of ATP production, biosynthesis and maintenance of redox balance, in which glutamine 
acts as an intermediate[42]. CB-839 also has antitumor activity in vivo, as shown by two studies of xenograft 
Figure 1. Pathways inhibited by CB-839, nivolumab, cabozantinib and everolimus. GLS: glutaminase; GSH: glutathione; ATP: adenosine 
triphosphate; αKG: alpha-ketoglutarate; PD-1: programmed death receptor 1; PD-L1: programmed death ligand 1
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models of TNBC[42]. In a patient-derived xenograft model, administration of 200mg/kg of CB-839 twice a 
day resulted in 61% tumor growth suppression when compared to untreated control. The HER2 + basal-like 
cell line JIMT-1 was used in a cell-line based xenograft model. Two treatment regimens were evaluated: CB-
839 on its own or in combination with the TNBC standard therapy paclitaxel. Administration of paclitaxel 
alone led to tumor reduction followed by tumor expansion, whereas CB-839 alone or in combination with 
paclitaxel reduced tumor growth with no tumor regrowth over time[42]. 
The activity of CB-839 was tested in a range of kidney cancer cell lines. Exposure to 1 µmol/L CB-839 for 
72h resulted in varying degrees of death of most but not all ccRCC lines tested, including 786-O, 769-P and 
A498. This variation was not associated with VHL mutant or wild-type status. In contrast, CB-839 did not 
seem to affect growth of six non-RCC cell lines, such as G402 and JMU-RTK2[44]. Other studies propose that 
glutamine becomes the preferred substrate for lipogenesis in VHL mutant ccRCC lines[45], suggesting that 
glutaminase inhibition should be cytotoxic in these cells. 
CB-839 monotherapy
CB-839 safety and tolerability in solid tumors is currently being evaluated in a first-in-man study estimated 
to be completed in September 2019 (ClinicalTrials.gov Identifier: NCT02071862)[46]. The study design contains 
both monotherapy and combination arms. As part of the combination, patients will receive CB-839 with 
drugs currently used for treatment of RCC, TNBC, NSCLC, mesothelioma and tumors with mutations in 
enzymes of the Krebs cycle. This multicenter, open-label, dose escalation study includes patients presenting 
with metastatic or locally advanced tumors. As monotherapy, patients will receive 100-800 mg CB-839 
twice- or three times daily in cycles lasting for 21 days. The 600 mg twice-daily was selected as the dose 
administered to the expansion cohort. In 2016, Calithera reported that 4 out of 75 patients experienced grade 
3 or 4 AEs. Out of 19 patients with several previous therapies (median = 3 therapies), 10 were ccRCC patients 
of which one achieved a confirmed ongoing partial response as of 8.3 months of therapy. To date, the study 
showed that continuous administration of CB-839 is characterized by an acceptable safety profile. Moreover, 
it significantly inhibits glutaminase and shows promising signs of clinical activity in various tumors, 
including RCC[47,48].  
CB-839 plus everolimus
Everolimus is an inhibitor that targets the kinase mTOR, which is a part of the PI3K/AKT/mTOR pathway 
[Figure 1], which is frequently mutated in RCC. Its crosstalk with VHL/HIF creates a positive feedback loop, 
where HIF-induced expression of growth factors activates PI3K/AKT pathway through RTKs. This in turn 
activates mTORC1 and mTORC2 leading to upregulation of HIF[49]. HIF translation and the consequent 
angiogenesis can be inhibited by repression of mTOR[50]. 
In vitro studies were performed using the ACHN cell line, which is thought to represent papillary RCC given 
its chromosomal aberration profile, characteristic c-met polymorphism and WT VHL status[51,52]. Five drug 
concentration combinations were evaluated: CB-839 at 18.8-300 nmol/L with everolimus at 1.6-100 nmol/L. 
For all combinations, cell survival was lower when compared to monotherapy. Pre-clinical studies of Caki-1 
xenografts showed that monotherapy with CB-839 or everolimus, resulted in tumor growth inhibition (TGI) 
of 51% and 52%, respectively. However, the combination of the two gave TGI of 85%[48]. 
An ongoing clinical study (ClinicalTrials.gov Identifier: NCT02071862) builds on these pre-clinical data, 
where the two drugs synergize and inhibit glutamine and glucose metabolism when combined[46]. So far it 
has shown that the combination is well tolerated in ccRCC and papillary carcinoma patients and CB-839 
does not increase the toxicities, compared to everolimus alone. The most common AEs were nausea and 
fatigue. A single case of dose-limiting toxicity was attributed to everolimus and after lowering the dose, the 
patient remained on study[48]. A 100% disease control rate (DCR) was reported for ccRCC patients (12/12) 
and 67% for papillary RCC patients (2/3). Preliminary PFS for both RCC histotypes was 8.5 months[48,53]. 
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CB-839 plus nivolumab
PD-1 is an inhibitory receptor expressed on activated T cells, which normally functions to dampen the 
immune response. PD-1 is engaged by PD-L1 (and PD-L2) expressed by tumor cells and infiltrating immune 
cells. Inhibition of the interaction between PD-1 and PD-L1 enhances anti-tumor responses, delays tumor 
growth, and may facilitate tumor rejection. Nivolumab is a fully humanized IgG4 PD-1 immune checkpoint 
inhibitor, which prevents ligand binding to PD-1 and promotes antitumor immunity by T cells [Figure 1][54]. 
T cells require glutamine for proliferation and compete with glutamine-addicted tumors for this amino acid, 
creating a metabolic checkpoint[31]. In contrast to reduced glutamine availability, GLS inhibition by CB-839 
does not affect T cell activation, their entry into S phase or their division in vitro. Instead, CB-839 reduces 
the use of glutamine by malignant cells relieving the metabolic checkpoint and making glutamine available 
for T cells. CB-839 is proposed to synergize with nivolumab in syngeneic colon tumor mouse models to 
improve T cell activation and proliferation, boosting their anti-cancer activity[55]. 
A Phase 1/2 study of CB-839 plus standard of care nivolumab is currently open and recruiting patients 
(ClinicalTrials.gov Identifier: NCT02771626). It aims to evaluate safety, pharmacokinetics and pharmacodynamics 
of the combination in patients with ccRCC, melanoma and NSCLC. Patients are receiving escalating doses of 
CB-839 twice daily and standard dose nivolumab to determine recommended Phase 2 dose (RP2D). In Phase 
2, patients are separated into five cohorts: ccRCC naïve to checkpoint inhibitors; ccRCC recently treated with 
nivolumab; ccRCC, melanoma or NSCLC with prior PD-1 therapy. Study completion is expected in June 
2019[56].
CB-839 plus cabozantinib
Cabozantinib is a signal transduction inhibitor and its targets include VEGFR, ARK and MET [Figure 1]. 
Early pre-clinical studies using the Caki-1 cell line and Caki-1 xenografts showed superiority of cabozantinib 
plus CB-839 over monotherapy when measuring its anti-proliferative effect. The combination reduced signal 
transduction more than cabozantinib alone by reducing pERK and pAKT proteins[57]. The two drugs also 
synergize to inhibit TCA cycle activity as measured by oxygen consumption rate. In xenograft models, 
where tumors of approximately 400 mm3 were treated with DMSO, CB-839, cabozantinib or a combination 
of the drugs, monotherapy resulted in slower tumor growth, which was enhanced in combination models[57].
Following in vitro and mouse studies, 13 patients with ccRCC or papillary RCC were enrolled into a Phase 1 
clinical trial. RP2D was evaluated at 800mg and no maximum tolerated dose was reached. Study outcomes 
including ORR of 40% and DCR of 100% in ccRCC, favorable safety profile and zero patients with PD, led to 
a randomized Phase 2 study, CANTANA[58]. This study is currently recruiting patients and aims to compare 
cabozantinib plus CB-839 vs. cabozantinib plus placebo in 298 patients with previous 2 or 3 lines of therapy. 
The key endpoints are PFS and OS with completion expected in 2022[58].
CONCLUSIONS AND FUTURE DIRECTIONS
The development of targeted therapy for RCC has revolutionized its treatment. RCC tumors are highly 
vascularized and current standard of treatment focuses mainly on drugs targeting angiogenesis by inhibiting 
VEGF and mTOR. However, high ITH and intrinsic and acquired therapy resistance prevents removal of 
all malignant cells. Residual tumor cells expand and lead to clinical relapse, creating the need for second- 
and further line therapies. Several combination therapies have been recently approved, however they are 
still in their early stages of use. Moreover, checkpoint inhibitors have not been used in the clinical setting to 
treat mRCC for long enough to fully evaluate their efficacy. Many RCC tumors are now being recognized to 
have altered metabolism in comparison to normal cells. Although efforts to formulate efficient glutaminase 
inhibitors are not a completely new concept, they are yet to be approved for use in the clinical setting. 
CB-839 has been shown to be well tolerated, but as monotherapy, its preliminary efficacy is limited to 
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achieving long-term stable disease. This suggests that it may be most effective in combination with other 
agents. In April 2018, the FDA granted Fast Track designation for CB-839 plus Cabo based on encouraging 
activity from a Phase 1 trial in heavily pre-treated mRCC patients. Combination therapy of CB-839 with 
everolimus requires more data to assess its efficacy. Since there is such a significant burden of resistance to 
currently available treatments, resistance may also be an issue for new treatments. Indeed, metabolomic 
studies of an allosteric and reversible inhibitor of GLS, C.968, found that lipid catabolism is activated to 
compensate for inhibition of glutaminolysis in several cancer cells[59]. This suggests that further genetic 
and metabolomic studies will be crucial for the successful implementation of CB-839 into routine clinical 
practice. 
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